scispace - formally typeset
Open AccessJournal ArticleDOI

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.

Reads0
Chats0
TLDR
In primary prevention without previous disease, aspirin is of uncertain net value as the reduction in occlusive events needs to be weighed against any increase in major bleeds.
About
This article is published in The Lancet.The article was published on 2009-05-30 and is currently open access. It has received 2954 citations till now. The article focuses on the topics: Stroke & Aspirin.

read more

Citations
More filters
Journal ArticleDOI

Antithrombotic drugs and risk of hemorrhagic stroke in the general population

TL;DR: Chronic low-dose aspirin treatment may have a protective effect on the risk of SAH, and warfarin users in this study cohort were at a much higher risk of ICH than those receiving no therapy, with a marked association with international normalized ratio >3.
Journal ArticleDOI

Gastrointestinal effects of aspirin.

TL;DR: There is growing evidence that long-term use of aspirin decreases the risk of colorectal cancer, even at low doses and physicians need to consider the benefits and harms for each individual patient in order to maximize the benefits of aspirin.
Journal ArticleDOI

Historical perspective and future directions in platelet research.

TL;DR: It is appropriate to consider it a Golden Age of Platelet Research and to recognize all of the investigators who have made important contributions to this remarkable achievement.
Journal ArticleDOI

Association of Antithrombotic Drug Use With Subdural Hematoma Risk

TL;DR: In Denmark, antithrombotic drug use was associated with higher risk of subdural hematoma and was highest when a VKA was used concurrently with an antiplatelet drug.
Journal ArticleDOI

Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement.

TL;DR: A systematic review on the effectiveness of aspirin to reduce the risk of CVD events, cardiovascular mortality, and all-cause mortality in persons without a history of CVB concludes with moderate certainty that initiating aspirin use for the primary prevention of CVC events in adults 60 years or older has no net benefit.
References
More filters
Journal ArticleDOI

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.

TL;DR: Statin therapy can safely reduce the 5-year incidence of major coronary events, coronary revascularisation, and stroke by about one fifth per mmol/L reduction in LDL cholesterol, largely irrespective of the initial lipid profile or other presenting characteristics.
Journal ArticleDOI

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

TL;DR: Aspirin (or another oral antiplatelet drug) is protective in most types of patient at increased risk of occlusive vascular events, including those with an acute myocardial infarction or ischaemic stroke, unstable or stable angina, previous myocardian infarctions, stroke or cerebral ischaemia, peripheral arterial disease, or atrial fibrillation.
Journal ArticleDOI

Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies

TL;DR: Below the range 22.5-25 kg/m(2), BMI was associated inversely with overall mortality, mainly because of strong inverse associations with respiratory disease and lung cancer, despite cigarette consumption per smoker varying little with BMI.
Related Papers (5)